

## **Supplementary appendix**

Supplement to: Song JY, Choi WS, Heo JY, et al. Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: a phase 1/2, randomized, placebo-controlled, observer-blinded trial.

## Table of contents

Table S1. Adverse event of special interest relevant to coronavirus disease 2019 .....	4
Table S2. List of potential immune-mediated diseases .....	5
Table S3. Solicited local adverse events - number of participants experiencing the events (safety set) .....	8
Table S4. Solicited systemic adverse events - number of participants experiencing the events (safety set) .....	9
Table S5. Hematologic laboratory monitoring for adverse events through 28 days after second-dose vaccination (safety set) .....	11
Table S6. Blood biochemistry test monitoring for adverse events through 28 days after second-dose vaccination (safety set) .....	12
Table S7. Unsolicited adverse events by category (safety set) .....	14
Table S8. Geometric mean concentrations and seroconversion rates of IgG antibody to the SARS-CoV-2-RBD by enzyme-linked immunosorbent assay (per-protocol set) .....	18
Table S9. Geometric mean titers and seroconversion rates of neutralizing antibody to the SARS-CoV-2 by pseudovirus-based neutralization assay (per-protocol set) .....	21
Table S10. Geometric mean titers and seroconversion rates of neutralizing antibody to the SARS-CoV-2 by plaque reduction neutralization test (per-protocol set) .....	24
Table S11. Geometric mean concentration and seroconversion rate of IgG antibody to the SARS-CoV-2-RBD in adults aged 19-64 years: analysis by enzyme-linked immunosorbent assay (per-protocol set) .....	26
Table S12. Geometric mean titer and seroconversion rate of neutralizing antibody titer to the SARS-CoV-2 in older adults aged 19-64 years: analysis by pseudovirus-based neutralization assay (per-protocol set) .....	29
Table S13. Geometric mean concentration and seroconversion rate of IgG antibody to the SARS-CoV-2-RBD in adults aged $\geq 65$ years: analysis by enzyme-linked immunosorbent assay (per-protocol set) .....	32
Table S14. Geometric mean titers and seroconversion rates of neutralizing antibody to the	

SARS-CoV-2 in adult aged $\geq$ 65 years: analysis by pseudovirus-based neutralization assay (per-protocol set) .....	35
Table S15. Cell-mediated response for CD4+ T cells expressing cytokines using intracellular cytokine staining (per-protocol set) .....	38
Figure S1. Clinical trial scheme .....	41
Figure S2. Boxplot for the IFN- $\gamma$ (A), TNF- $\alpha$ (B), IL-2 (C), IL-4 (D), IL-5 (E) of cell-mediated immune responses for CD4+ T-cells expressing cytokines using intracellular cytokine staining .....	42
Figure S3. Age-stratified analysis of solicited local (A) and systemic (B) adverse events within 7 days after first-dose and second-dose (proportion of participants with adverse events) .....	47
Figure S4. Cross-reactive immunogenicity against the delta variant in GBP510 adjuvanted with AS03 recipients, assessed by the plaque reduction neutralization test .....	49

**Table S1.** Adverse event of special interest (AESI) relevant to coronavirus disease 2019 (COVID-19)

Body System	AESI relevant to COVID-19
Immunologic	Enhanced disease following immunization Anaphylaxis Vasculitis
Respiratory	Acute Respiratory Distress Syndrome (ARDS)
Cardiac	Acute cardiac injury including: <ul style="list-style-type: none"><li>▪ Microangiopathy</li><li>▪ Heart failure and cardiogenic shock</li><li>▪ Stress cardiomyopathy</li><li>▪ Coronary artery disease</li><li>▪ Arrhythmia</li><li>▪ Myocarditis, pericarditis</li></ul>
Hematologic	Coagulation disorder: <ul style="list-style-type: none"><li>▪ Deep vein thrombosis</li><li>▪ Pulmonary embolus</li><li>▪ Cerebrovascular stroke</li><li>▪ Limb ischemia</li><li>▪ Hemorrhagic disease</li><li>▪ Thrombocytopenia</li></ul>
Renal	Acute kidney injury
Gastrointestinal	Liver injury
Neurologic	Guillain Barré Syndrome Generalized convulsion Anosmia, ageusia Meningoencephalitis Acute disseminated encephalomyelitis
Dermatologic	Chilblain-like lesions Single organ cutaneous vasculitis Erythema multiforme

**Table S2.** List of potential immune-mediated diseases<sup>6</sup>

Neuroinflammatory disorders	Musculoskeletal disorders	Skin disorders
<ul style="list-style-type: none"> <li>▪ Cranial nerve neuropathy, including paralysis and paresis (eg, Bell's palsy).</li> <li>▪ Optic neuritis.</li> <li>▪ Multiple sclerosis.</li> <li>▪ Transverse myelitis.</li> <li>▪ Guillain-Barré syndrome, including Miller Fisher syndrome and other variants.</li> <li>▪ Acute disseminated encephalomyelitis, including site specific variants, eg, noninfectious encephalitis, encephalomyelitis, myelitis, myeloradiculoneuritis.</li> <li>▪ Myasthenia gravis, including Lambert-Eaton myasthenic syndrome.</li> <li>▪ Demyelinating peripheral neuropathies including:           <ul style="list-style-type: none"> <li>- Chronic inflammatory demyelinating polyneuropathy.</li> <li>- Multifocal motor neuropathy.</li> <li>- Polyneuropathies associated with monoclonal gammopathy.</li> </ul> </li> <li>▪ Narcolepsy.</li> </ul>	<ul style="list-style-type: none"> <li>▪ Systemic lupus erythematosus and associated conditions.</li> <li>▪ Systemic scleroderma (systemic sclerosis), including:           <ul style="list-style-type: none"> <li>- Diffuse scleroderma.</li> <li>- CREST syndrome.</li> </ul> </li> <li>▪ Idiopathic inflammatory myopathies, including:           <ul style="list-style-type: none"> <li>- Dermatomyositis.</li> <li>- Polymyositis.</li> </ul> </li> <li>▪ Anti-synthetase syndrome.</li> <li>▪ Rheumatoid arthritis and associated conditions including:           <ul style="list-style-type: none"> <li>- Juvenile idiopathic arthritis.</li> <li>- Still's disease.</li> </ul> </li> <li>▪ Polymyalgia rheumatica.</li> <li>▪ Spondyloarthropathies, including:           <ul style="list-style-type: none"> <li>- Ankylosing spondylitis.</li> <li>- Reactive arthritis (Reiter's syndrome).</li> <li>- Undifferentiated spondyloarthritis.</li> <li>- Psoriatic arthritis.</li> <li>- Enteropathic arthritis.</li> </ul> </li> <li>▪ Relapsing polychondritis.</li> <li>▪ Mixed connective tissue disorder.</li> <li>▪ Gout.</li> </ul>	<ul style="list-style-type: none"> <li>▪ Psoriasis.</li> <li>▪ Vitiligo.</li> <li>▪ Erythema nodosum.</li> <li>▪ Autoimmune bullous skin diseases (including pemphigus, pemphigoid, and dermatitis herpetiformis).</li> <li>▪ Lichen planus.</li> <li>▪ Sweet's syndrome.</li> <li>▪ Localized scleroderma (morphea).</li> </ul>
Vasculitis	Blood disorders	Others
<ul style="list-style-type: none"> <li>▪ Large vessels vasculitis including:           <ul style="list-style-type: none"> <li>- Giant cell arteritis</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>▪ Autoimmune hemolytic anemia.</li> <li>▪ Autoimmune</li> </ul>	<ul style="list-style-type: none"> <li>▪ Autoimmune glomerulonephritis including:</li> </ul>

<ul style="list-style-type: none"> <li>(temporal arteritis).</li> <li>- Takayasu's arteritis.</li> <li>▪ Medium sized and/or small vessels vasculitis including:           <ul style="list-style-type: none"> <li>- Polyarteritis nodosa.</li> <li>- Kawasaki's disease.</li> <li>- Microscopic polyangiitis.</li> <li>- Wegener's granulomatosis (granulomatosis with polyangiitis).</li> <li>- Churg-Strauss syndrome (allergic granulomatous angiitis or eosinophilic granulomatosis with polyangiitis).</li> <li>- Buerger's disease (thromboangiitis obliterans).</li> <li>- Necrotizing vasculitis (cutaneous or systemic).</li> <li>- Anti-Neutrophil Cytoplasmic Antibody (ANCA) positive vasculitis (type unspecified).</li> <li>- Henoch-Schonlein purpura (IgA vasculitis).</li> <li>- Behcet's syndrome.</li> <li>- Leukocytoclastic vasculitis.</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>▪ thrombocytopenia.</li> <li>▪ Antiphospholipid syndrome.</li> <li>▪ Pernicious anemia.</li> <li>▪ Autoimmune aplastic anemia.</li> <li>▪ Autoimmune neutropenia.</li> <li>▪ Autoimmune pancytopenia.</li> </ul>	<ul style="list-style-type: none"> <li>- IgA nephropathy.</li> <li>- Glomerulonephritis rapidly progressive.</li> <li>- Membranous glomerulonephritis.</li> <li>- Membranoproliferative glomerulonephritis.</li> <li>- Mesangiproliferative glomerulonephritis.</li> <li>- Tubulointerstitial nephritis and uveitis syndrome.</li> <li>▪ Ocular autoimmune diseases including:           <ul style="list-style-type: none"> <li>- Autoimmune uveitis.</li> <li>- Autoimmune retinitis.</li> </ul> </li> <li>▪ Autoimmune myocarditis.</li> <li>▪ Sarcoidosis.</li> <li>▪ Stevens-Johnson syndrome.</li> <li>▪ Sjögren's syndrome.</li> <li>▪ Alopecia areata.</li> <li>▪ Idiopathic pulmonary fibrosis.</li> <li>▪ Goodpasture syndrome.</li> <li>▪ Raynaud's phenomenon.</li> </ul>
Liver disorders	Gastrointestinal disorders	Endocrine disorders
<ul style="list-style-type: none"> <li>▪ Autoimmune hepatitis.</li> <li>▪ Primary biliary cirrhosis.</li> <li>▪ Primary sclerosing cholangitis.</li> </ul>	<ul style="list-style-type: none"> <li>▪ Inflammatory bowel disease, including:           <ul style="list-style-type: none"> <li>- Crohn's disease.</li> <li>- Ulcerative colitis.</li> <li>- Microscopic</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>▪ Autoimmune thyroiditis (Hashimoto thyroiditis).</li> <li>▪ Grave's or Basedow's disease.</li> <li>▪ Diabetes mellitus type 1.</li> </ul>

<ul style="list-style-type: none"> <li>■ Autoimmune cholangitis.</li> </ul>	<ul style="list-style-type: none"> <li>colitis.</li> <li>- Ulcerative proctitis.</li> <li>■ Celiac disease.</li> <li>■ Autoimmune pancreatitis.</li> </ul>	<ul style="list-style-type: none"> <li>■ Addison's disease.</li> <li>■ Polyglandular autoimmune syndrome.</li> <li>■ Autoimmune hypophysitis.</li> </ul>
---	--	--

**Table S3. Solicited local adverse events - number of participants experiencing the events (safety set)**

	10µg GBP510 with AS03 (N = 101)	10µg GBP510 (N = 10)	25µg GBP510 with AS03 (N = 104)	25µg GBP510 (N = 51)	Placebo (N = 61)
Adverse Events after any vaccine injection, n (%)					
Injection Site Pain	89 (88·12)	5 (50·00)	96 (92·31)	34 (66·67)	13 (21·31)
Injection Site Redness	8 (7·92)	0 (0·00)	11 (10·58)	0 (0·00)	0 (0·00)
Injection Site Swelling	11 (10·89)	0 (0·00)	14 (13·46)	2 (3·92)	0 (0·00)
Adverse Events after the 1 <sup>st</sup> vaccination, n (%)					
Injection site pain	83 (82·18)	2 (20·00)	89 (85·58)	25 (49·02)	8 (13·11)
Injection site redness	2 (1·98)	0 (0·00)	3 (2·88)	0 (0·00)	0 (0·00)
Injection site swelling	5 (4·95)	0 (0·00)	11 (10·58)	2 (3·92)	0 (0·00)
Adverse Events after the 2 <sup>nd</sup> vaccination, n (%)					
Injection site pain	79 (78·22)	4 (40·00)	89 (85·58)	24 (47·06)	8 (13·11)
Injection site redness	7 (6·93)	0 (0·00)	10 (9·62)	0 (0·00)	0 (0·00)
Injection site swelling	9 (8·91)	0 (0·00)	8 (7·69)	0 (0·00)	0 (0·00)

#: n / (No. of participant in Safety Set by group) \* 100

95% Confidence Interval for the percentage of participants with AE is calculated by Clopper-Pearson Methods.

n: number of participants

**Table S4. Solicited systemic adverse events - number of participants experiencing the events (safety set)**

	10µg GBP510 with AS03 (N = 101)	10µg GBP510 (N = 10)	25µg GBP510 with AS03 (N = 104)	25µg GBP510 (N = 51)	Placebo (N = 61)
Adverse Events after any vaccine injection, n (%)					
Fever	10 (9·90)	0 (0·00)	18 (17·31)	0 (0·00)	1 (1·64)
Nausea/vomiting	18 (17·82)	2 (20·00)	24 (23·08)	3 (5·88)	6 (9·84)
Diarrhea	18 (17·82)	2 (20·00)	17 (16·35)	9 (17·65)	5 (8·20)
Headache	54 (53·47)	4 (40·00)	59 (56·73)	16 (31·37)	21 (34·43)
Fatigue	80 (79·21)	4 (40·00)	78 (75·00)	31 (60·78)	30 (49·18)
Myalgia	79 (78·22)	4 (40·00)	83 (79·81)	24 (47·06)	19 (31·15)
Arthralgia	39 (38·61)	1 (10·00)	42 (40·38)	11 (21·57)	10 (16·39)
Chills	44 (43·56)	1 (10·00)	57 (54·81)	4 (7·84)	10 (16·39)
Adverse events after the first dose, n (%)					
Fever	0 (0·00)	0 (0·00)	2 (1·92)	0 (0·00)	1 (1·64)
Nausea/vomiting	6 (5·94)	1 (10·00)	9 (8·65)	1 (1·96)	3 (4·92)
Diarrhea	9 (8·91)	2 (20·00)	11 (10·58)	5 (9·80)	4 (6·56)
Headache	24 (23·76)	3 (30·00)	26 (25·00)	10 (19·61)	12 (19·67)
Fatigue	56 (55·45)	3 (30·00)	54 (51·92)	24 (47·06)	25 (40·98)
Myalgia	54 (53·47)	2 (20·00)	55 (52·88)	19 (37·25)	13 (21·31)
Arthralgia	20 (19·80)	1 (10·00)	21 (20·19)	6 (11·76)	3 (4·92)
Chills	11 (10·89)	1 (10·00)	14 (13·46)	4 (7·84)	1 (1·64)
Adverse events after the second dose, n (%)					
Fever	10 (9·90)	0 (0·00)	17 (16·35)	0 (0·00)	0 (0·00)
Nausea/vomiting	14 (13·86)	1 (10·00)	19 (18·27)	3 (5·88)	3 (4·92)
Diarrhea	12 (11·88)	0 (0·00)	9 (8·65)	6 (11·76)	2 (3·28)
Headache	46 (45·54)	2 (20·00)	52 (50·00)	10 (19·61)	13 (21·31)
Fatigue	69 (68·32)	2 (20·00)	77 (74·04)	22 (43·14)	24 (39·34)

Myalgia	68 (67·33)	3 (30·00)	76 (73·08)	15 (29·41)	11 (18·03)
Arthralgia	33 (32·67)	0 (0·00)	36 (34·62)	5 (9·80)	8 (13·11)
Chills	41 (40·59)	0 (0·00)	53 (50·96)	1 (1·96)	10 (16·39)

%: n / (No. of participant in Safety Set by group) \* 100

95% Confidence Interval for the percentage of participants with AE is calculated by Clopper-Pearson Methods.

n: number of participants

**Table S5. Hematologic laboratory monitoring for adverse events through 28 days after second-dose vaccination (safety set)**

Screening	10µg GBP510 with AS03 (N = 101)		10µg GBP510 (N = 10)		25µg GBP510 with AS03 (N = 104)		25µg GBP510 (N = 51)		Placebo (N = 61)	
	Normal/NCS	CS	Normal/NCS	CS	Normal/NCS	CS	Normal/NCS	CS	Normal/NCS	CS
<b>WBC, n (%)</b>										
Normal/NCS	97 (98·98)	1 (1·02)	10 (100·00)	0 (0·00)	103 (100·00)	0 (0·00)	49 (100·00)	0 (0·00)	60 (100·00)	0 (0·00)
CS	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
<b>RBC, n (%)</b>										
Normal/NCS	98 (100·00)	0 (0·00)	10 (100·00)	0 (0·00)	103 (100·00)	0 (0·00)	49 (100·00)	0 (0·00)	60 (100·00)	0 (0·00)
CS	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
<b>Hemoglobin, n (%)</b>										
Normal/NCS	98 (100·00)	0 (0·00)	10 (100·00)	0 (0·00)	103 (100·00)	0 (0·00)	49 (100·00)	0 (0·00)	60 (100·00)	0 (0·00)
CS	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
<b>Hematocrit, n (%)</b>										
Normal/NCS	98 (100·00)	0 (0·00)	10 (100·00)	0 (0·00)	103 (100·00)	0 (0·00)	49 (100·00)	0 (0·00)	60 (100·00)	0 (0·00)
CS	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
<b>Platelet, n (%)</b>										
Normal/NCS	98 (100·00)	0 (0·00)	10 (100·00)	0 (0·00)	103 (100·00)	0 (0·00)	49 (100·00)	0 (0·00)	60 (100·00)	0 (0·00)
CS	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
<b>Neutrophil, n (%)</b>										
Normal/NCS	98 (100·00)	0 (0·00)	10 (100·00)	0 (0·00)	103 (100·00)	0 (0·00)	49 (100·00)	0 (0·00)	60 (100·00)	0 (0·00)
CS	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
<b>Lymphocytes, n (%)</b>										
Normal/NCS	98 (100·00)	0 (0·00)	10 (100·00)	0 (0·00)	103 (100·00)	0 (0·00)	49 (100·00)	0 (0·00)	60 (100·00)	0 (0·00)
CS	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
<b>Eosinophils, n (%)</b>										
Normal/NCS	98 (100·00)	0 (0·00)	10 (100·00)	0 (0·00)	103 (100·00)	0 (0·00)	49 (100·00)	0 (0·00)	59 (98·33)	1 (1·67)
CS	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)

NCS, not clinically significant abnormal; CS, clinically significant abnormal

Participants evaluated both screening and visit 7 were analyzed.

%: n / (No. of participants in each group) \* 100; it is calculated based on the total number of participants who were available on visit 7.

n: number of participants

**Table S6. Blood biochemistry test monitoring for adverse events through 28 days after second-dose vaccination (safety set)**

Screening	10µg GBP510 with AS03 (N = 101)		10µg GBP510 (N = 10)		25µg GBP510 with AS03 (N = 104)		25µg GBP510 (N = 51)		Placebo (N = 61)	
	Normal/NCS	CS	Normal/NCS	CS	Normal/NCS	CS	Normal/NCS	CS	Normal/NCS	CS
Glucose, n (%)										
Normal/NCS	98 (100·00)	0 (0·00)	10 (100·00)	0 (0·00)	103 (100·00)	0 (0·00)	49 (100·00)	0 (0·00)	60 (100·00)	0 (0·00)
CS	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
Aspartate transaminase (AST), n (%)										
Normal/NCS	98 (100·00)	0 (0·00)	10 (100·00)	0 (0·00)	103 (100·00)	0 (0·00)	49 (100·00)	0 (0·00)	59 (98·33)	1 (1·67)
CS	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
Alanine transferase (ALT), n (%)										
Normal/NCS	97 (98·98)	1 (1·02)	10 (100·00)	0 (0·00)	103 (100·00)	0 (0·00)	49 (100·00)	0 (0·00)	59 (98·33)	1 (1·67)
CS	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
Alkaline phosphatase (ALP), n (%)										
Normal/NCS	98 (100·00)	0 (0·00)	10 (100·00)	0 (0·00)	103 (100·00)	0 (0·00)	49 (100·00)	0 (0·00)	60 (100·00)	0 (0·00)
CS	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
Total bilirubin, n (%)										
Normal/NCS	98 (100·00)	0 (0·00)	10 (100·00)	0 (0·00)	103 (100·00)	0 (0·00)	49 (100·00)	0 (0·00)	60 (100·00)	0 (0·00)
CS	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
Total protein, n (%)										
Normal/NCS	98 (100·00)	0 (0·00)	10 (100·00)	0 (0·00)	103 (100·00)	0 (0·00)	49 (100·00)	0 (0·00)	60 (100·00)	0 (0·00)
CS	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
Albumin, n (%)										
Normal/NCS	98 (100·00)	0 (0·00)	10 (100·00)	0 (0·00)	103 (100·00)	0 (0·00)	49 (100·00)	0 (0·00)	60 (100·00)	0 (0·00)
CS	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
BUN, n (%)										
Normal/NCS	98 (100·00)	0 (0·00)	10 (100·00)	0 (0·00)	103 (100·00)	0 (0·00)	49 (100·00)	0 (0·00)	60 (100·00)	0 (0·00)
CS	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
Creatinine, n (%)										
Normal/NCS	98 (100·00)	0 (0·00)	10 (100·00)	0 (0·00)	103 (100·00)	0 (0·00)	49 (100·00)	0 (0·00)	60 (100·00)	0 (0·00)
CS	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
Uric acid, n (%)										
Normal/NCS	98 (100·00)	0 (0·00)	10 (100·00)	0 (0·00)	103 (100·00)	0 (0·00)	49 (100·00)	0 (0·00)	59 (98·33)	1 (1·67)

Screening	10µg GBP510 with AS03 (N = 101)		10µg GBP510 (N = 10)		25µg GBP510 with AS03 (N = 104)		25µg GBP510 (N = 51)		Placebo (N = 61)	
	Normal/NCS	CS	Normal/NCS	CS	Normal/NCS	CS	Normal/NCS	CS	Normal/NCS	CS
	CS	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
Total cholesterol, n (%)										
Normal/NCS	98 (100·00)	0 (0·00)	10 (100·00)	0 (0·00)	103 (100·00)	0 (0·00)	48 (97·96)	1 (2·04)	60 (100·00)	0 (0·00)
CS	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
Triglyceride, n (%)										
Normal/NCS	95 (96·94)	0 (0·00)	10 (100·00)	0 (0·00)	100 (97·09)	3 (2·91)	49 (100·00)	0 (0·00)	59 (98·33)	1 (1·67)
CS	3 (3·06)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
Calcium, n (%)										
Normal/NCS	98 (100·00)	0 (0·00)	10 (100·00)	0 (0·00)	103 (100·00)	0 (0·00)	49 (100·00)	0 (0·00)	60 (100·00)	0 (0·00)
CS	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
Phosphorus, n (%)										
Normal/NCS	98 (100·00)	0 (0·00)	10 (100·00)	0 (0·00)	103 (100·00)	0 (0·00)	49 (100·00)	0 (0·00)	60 (100·00)	0 (0·00)
CS	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
Sodium, n (%)										
Normal/NCS	98 (100·00)	0 (0·00)	10 (100·00)	0 (0·00)	103 (100·00)	0 (0·00)	49 (100·00)	0 (0·00)	60 (100·00)	0 (0·00)
CS	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
Potassium, n (%)										
Normal/NCS	98 (100·00)	0 (0·00)	10 (100·00)	0 (0·00)	103 (100·00)	0 (0·00)	49 (100·00)	0 (0·00)	60 (100·00)	0 (0·00)
CS	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)

NCS, not clinically significant abnormal; CS, clinically significant abnormal; BUN, blood urea nitrogen

Participants evaluated at both screening and visit 7 were analyzed.

%: n / (No. of participants in each group) \* 100; it is calculated based on the total number of participants who were available on visit 7.

n: number of participants

**Table S7. Unsolicited adverse events by category (safety set)**

	<b>10µg GBP510 with AS03 (N = 101)</b>	<b>10µg GBP510 (N = 10)</b>	<b>25µg GBP510 with AS03 (N = 104)</b>	<b>25µg GBP510 (N = 51)</b>	<b>Placebo (N = 61)</b>
Adverse events after any vaccine injection					
Total number of AE occurrences (n)	26	3	31	16	16
Maximum severity, No. of AEs (%)					
Grade 1 (mild)	21 (80·77)	1 (33·33)	18 (58·06)	13 (81·25)	14 (87·50)
Grade 2 (moderate)	3 (11·54)	2 (66·67)	11 (35·48)	3 (18·75)	2 (12·50)
Grade 3 (severe)	2 (7·69)	0 (0·00)	2 (6·45)	0 (0·00)	0 (0·00)
Grade 4 (life threatening)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
Seriousness, number of AEs (%)					
Yes	0 (0·00)	0 (0·00)	1 (3·23)	2 (12·50)	0 (0·00)
No	26 (100·00)	3 (100·00)	30 (96·77)	14 (87·50)	16 (100·00)
Outcome, number of AEs (%)					
Recovered/resolved	21 (80·77)	3 (100·00)	29 (93·55)	12 (75·00)	15 (93·75)
Recovering/resolving	3 (11·54)	0 (0·00)	1 (3·23)	2 (12·50)	1 (6·25)
Not recovered/not resolved	2 (7·69)	0 (0·00)	1 (3·23)	1 (6·25)	0 (0·00)
Stabilized	1 (3·85)	0 (0·00)	1 (3·23)	1 (6·25)	0 (0·00)
Not stabilized	1 (3·85)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
Recovered/resolved with sequelae	0 (0·00)	0 (0·00)	0 (0·00)	1 (6·25)	0 (0·00)
Fatal	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
Unknown	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
Causality, number of AEs (%)					
Related	7 (26·92)	0 (0·00)	9 (29·03)	4 (25·00)	2 (12·50)
Not-related	19 (73·08)	3 (100·00)	22 (70·97)	12 (75·00)	14 (87·50)
Action taken with IP, No. of AEs (%)					
Stop vaccination	0 (0·00)	0 (0·00)	0 (0·00)	4 (25·00)	0 (0·00)
Continue to vaccination	12 (46·15)	2 (66·67)	17 (54·84)	7 (43·75)	7 (43·75)
Unknown	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
Not applicable	14 (53·85)	1 (33·33)	14 (45·16)	5 (31·25)	9 (56·25)
Medication (including other treatment), number of AEs (%)					
Yes	15 (57·69)	2 (66·67)	18 (58·06)	12 (75·00)	10 (62·50)
No	11 (42·31)	1 (33·33)	13 (41·94)	4 (25·00)	6 (37·50)
Immediate systemic reaction, number of AEs (%)					
Yes	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
No	26 (100·00)	3 (100·00)	31 (100·00)	16 (100·00)	16 (100·00)

	<b>10µg GBP510 with AS03 (N = 101)</b>	<b>10µg GBP510 (N = 10)</b>	<b>25µg GBP510 with AS03 (N = 104)</b>	<b>25µg GBP510 (N = 51)</b>	<b>Placebo (N = 61)</b>
MAAE, number of AEs (%)					
Yes	12 (46·15)	2 (66·67)	9 (29·03)	8 (50·00)	5 (31·25)
Hospitalization	0 (0·00)	0 (0·00)	1 (3·23)	1 (6·25)	0 (0·00)
ER visit	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
Other visit to a healthcare professional	12 (46·15)	2 (66·67)	8 (25·81)	7 (43·75)	5 (31·25)
No	14 (53·85)	1 (33·33)	22 (70·97)	8 (50·00)	11 (68·75)
AESI, number of AEs (%)					
Yes	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
No	26 (100·00)	3 (100·00)	31 (100·00)	16 (100·00)	16 (100·00)
Adverse events after the 1 <sup>st</sup> vaccination					
Total number of AE occurrences (n)	12	2	17	11	7
Maximum severity, number of AEs (%)					
Grade 1 (mild)	11 (91·67)	1 (50·00)	9 (52·94)	9 (81·82)	6 (85·71)
Grade 2 (moderate)	0 (0·00)	1 (50·00)	6 (35·29)	2 (18·18)	1 (14·29)
Grade 3 (severe)	1 (8·33)	0 (0·00)	2 (11·76)	0 (0·00)	0 (0·00)
Grade 4 (life threatening)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
Seriousness, number of AEs (%)					
Yes	0 (0·00)	0 (0·00)	1 (5·88)	2 (18·18)	0 (0·00)
No	12 (100·00)	2 (100·00)	16 (94·12)	9 (81·82)	7 (100·00)
Outcome, number of AEs (%)					
Recovered/resolved	9 (75·00)	2 (100·00)	17 (100·00)	7 (63·64)	7 (100·00)
Recovering/resolving	2 (16·67)	0 (0·00)	0 (0·00)	2 (18·18)	0 (0·00)
Not recovered/not resolved	1 (8·33)	0 (0·00)	0 (0·00)	1 (9·09)	0 (0·00)
Stabilized	0 (0·00)	0 (0·00)	0 (0·00)	1 (9·09)	0 (0·00)
Not stabilized	1 (8·33)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
Recovered/resolved with sequelae	0 (0·00)	0 (0·00)	0 (0·00)	1 (9·09)	0 (0·00)
Fatal	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
Unknown	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
Causality, number of AEs (%)					
Related	1 (8·33)	0 (0·00)	5 (29·41)	4 (36·36)	1 (14·29)
Not-related	11 (91·67)	2 (100·00)	12 (70·59)	7 (63·64)	6 (85·71)
Action taken with IP, number of AEs (%)					
Stop vaccination	0 (0·00)	0 (0·00)	0 (0·00)	4 (36·36)	0 (0·00)
Continue to vaccination	12 (100·00)	2 (100·00)	17 (100·00)	7 (63·64)	7 (100·00)
Unknown	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)

	<b>10µg GBP510 with AS03 (N = 101)</b>	<b>10µg GBP510 (N = 10)</b>	<b>25µg GBP510 with AS03 (N = 104)</b>	<b>25µg GBP510 (N = 51)</b>	<b>Placebo (N = 61)</b>
Not applicable	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
Medication (including other treatment), number of AEs (%)					
Yes	9 (75·00)	1 (50·00)	11 (64·71)	10 (90·91)	7 (100·00)
No	3 (25·00)	1 (50·00)	6 (35·29)	1 (9·09)	0 (0·00)
Immediate systemic reaction, number of AEs (%)					
Yes	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
No	12 (100·00)	2 (100·00)	17 (100·00)	11 (100·00)	7 (100·00)
MAAE, number of AEs (%)					
Yes	5 (41·67)	2 (100·00)	6 (35·29)	7 (63·64)	2 (28·57)
Hospitalization	0 (0·00)	0 (0·00)	1 (5·88)	1 (9·09)	0 (0·00)
ER visit	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
Other visit to a healthcare professional	5 (41·67)	2 (100·00)	5 (29·41)	6 (54·55)	2 (28·57)
No	7 (58·33)	0 (0·00)	11 (64·71)	4 (36·36)	5 (71·43)
AESI, number of AEs (%)					
Yes	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
No	12 (100·00)	2 (100·00)	17 (100·00)	11 (100·00)	7 (100·00)
Adverse events after the 2 <sup>nd</sup> vaccination					
Total number of AE occurrences (n)	14	1	14	5	9
Maximum severity, number of AEs (%)					
Grade 1 (mild)	10 (71·43)	0 (0·00)	9 (64·29)	4 (80·00)	8 (88·89)
Grade 2 (moderate)	3 (21·43)	1 (100·00)	5 (35·71)	1 (20·00)	1 (11·11)
Grade 3 (severe)	1 (7·14)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
Grade 4 (life threatening)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
Seriousness, number of AEs (%)					
Yes	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
No	14 (100·00)	1 (100·00)	14 (100·00)	5 (100·00)	9 (100·00)
Outcome, number of AEs (%)					
Recovered/resolved	12 (85·71)	1 (100·00)	12 (85·71)	5 (100·00)	8 (88·89)
Recovering/resolving	1 (7·14)	0 (0·00)	1 (7·14)	0 (0·00)	1 (11·11)
Not recovered/not resolved	1 (7·14)	0 (0·00)	1 (7·14)	0 (0·00)	0 (0·00)
Stabilized	1 (7·14)	0 (0·00)	1 (7·14)	0 (0·00)	0 (0·00)
Not stabilized	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
Recovered/resolved with sequelae	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
Fatal	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
Unknown	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)

	<b>10µg GBP510 with AS03 (N = 101)</b>	<b>10µg GBP510 (N = 10)</b>	<b>25µg GBP510 with AS03 (N = 104)</b>	<b>25µg GBP510 (N = 51)</b>	<b>Placebo (N = 61)</b>
Causality, number of AEs (%)					
Related	6 (42·86)	0 (0·00)	4 (28·57)	0 (0·00)	1 (11·11)
Not-related	8 (57·14)	1 (100·00)	10 (71·43)	5 (100·00)	8 (88·89)
Action taken with IP, number of AEs (%)					
Stop vaccination	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
Continue to vaccination	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
Unknown	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
Not applicable	14 (100·00)	1 (100·00)	14 (100·00)	5 (100·00)	9 (100·00)
Medication (including other treatment), number of AEs (%)					
Yes	6 (42·86)	1 (100·00)	7 (50·00)	2 (40·00)	3 (33·33)
No	8 (57·14)	0 (0·00)	7 (50·00)	3 (60·00)	6 (66·67)
Immediate systemic reaction, number of AEs (%)					
Yes	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
No	14 (100·00)	1 (100·00)	14 (100·00)	5 (100·00)	9 (100·00)
MAAE, number of AEs (%)					
Yes	7 (50·00)	0 (0·00)	3 (21·43)	1 (20·00)	3 (33·33)
Hospitalization	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
ER visit	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
Other visit to a healthcare professional	7 (50·00)	0 (0·00)	3 (21·43)	1 (20·00)	3 (33·33)
No	7 (50·00)	1 (100·00)	11 (78·57)	4 (80·00)	6 (66·67)
AESI, number of AEs (%)					
Yes	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)	0 (0·00)
No	14 (100·00)	1 (100·00)	14 (100·00)	5 (100·00)	9 (100·00)

AEs, adverse events; SAE, serious adverse events; MAAE, medically attended adverse events; adverse events of special interest (AESIs); MAADRS, medically attended adverse drug reactions; IP, investigational product; ER, emergency room.

%: n / (No. of AEs in Safety Set by group) \* 100

n: number of AE

**Table S8. Geometric mean concentrations and seroconversion rates of IgG antibody titer to the SARS-CoV-2-RBD by enzyme-linked immunosorbent assay (per-protocol set)**

	10µg GBP510 with AS03 (N = 93)	10µg GBP510 (N = 10)	25µg GBP510 with AS03 (N = 96)	25µg GBP510 (N = 45)	Placebo (N = 58)
Geometric mean titer and seroconversion rate					
Baseline					
n	93	10	96	45	58
GMC ± standard deviation (BAU/mL)	15·08 ± 1·69	10·95 ± 1·61	13·85 ± 1·72	16·34 ± 1·66	12·51 ± 1·64
95% CI (lower, upper)	(13·54, 16·80)	(7·78, 15·40)	(12·42, 15·46)	(14·04, 19·03)	(10·97, 14·25)
P-value vs. placebo	0·0311	0·4339	0·2422	0·0084	
P-value vs. GBP510 10µg with AS03		0·0671	0·2750		
P-value vs. GBP510 25µg with AS03				0·0862	
Visit 4 (4 weeks post-1 <sup>st</sup> vaccination)					
n	93	10	96	45	58
GMC ± standard deviation (BAU/mL)	111·85 ± 2·10	37·72 ± 2·03	129·00 ± 2·09	28·63 ± 1·72	12·71 ± 1·71
95% CI (lower, upper)	(96·00, 130·31)	(22·74, 62·56)	(111·05, 149·84)	(24·32, 33·71)	(11·04, 14·63)
P-value vs. placebo	<0·0001	<0·0001	<0·0001	<0·0001	
P-value vs. GBP510 10µg with AS03		<0·0001	0·1871		
P-value vs. GBP510 25µg with AS03				<0·0001	
GMFR ± standard deviation	7·42 ± 2·48	3·45 ± 1·91	9·31 ± 2·34	1·75 ± 1·94	1·02 ± 1·90
95% CI (lower, upper)	(6·15, 8·94)	(2·17, 5·47)	(7·84, 11·06)	(1·44, 2·14)	(0·86, 1·20)
P-value vs. placebo	<0·0001	<0·0001	<0·0001	<0·0001	
P-value vs. GBP510 10µg with AS03		0·0110	0·0774		
P-value vs. GBP510 25µg with AS03				<0·0001	
SCR, n (%)	68 (73·12)	4 (40·00)	79 (82·29)	5 (11·11)	0 (0·00)
95% CI (lower, upper)	(62·92, 81·79)	(12·16, 73·76)	(73·17, 89·33)	(3·71, 24·05)	(0·00, 6·16)
P-value vs. placebo	<0·0001	0·0003	<0·0001	0·0140	
P-value vs. GBP510 10µg with AS03		0·0624	0·1294		
P-value vs. GBP510 25µg with AS03				<0·0001	
Visit 6 (2 weeks post-2 <sup>nd</sup> vaccination)					
n	93	10	96	45	58
GMC ± standard deviation (BAU/mL)	2,163·59 ± 1·89	155·30 ± 3·05	2,599·22 ± 1·86	112·40 ± 2·75	10·56 ± 1·63
95% CI (lower, upper)	(1,898·11, 2,466·20)	(70·02, 344·47)	(2,292·62, 2,946·83)	(82·92, 152·37)	(9·28, 12·01)

	<b>10µg GBP510 with AS03 (N = 93)</b>	<b>10µg GBP510 (N = 10)</b>	<b>25µg GBP510 with AS03 (N = 96)</b>	<b>25µg GBP510 (N = 45)</b>	<b>Placebo (N = 58)</b>
P-value vs. placebo	<0·0001	<0·0001	<0·0001	<0·0001	
P-value vs. GBP510 10µg with AS03		<0·0001	0·0459		
P-value vs. GBP510 25µg with AS03				<0·0001	
GMFR ± standard deviation	143·47 ± 2·33	14·19 ± 2·58	187·61 ± 2·09	6·88 ± 2·93	0·84 ± 1·66
95% CI (lower, upper)	(120·48, 170·85)	(7·21, 27·92)	(161·61, 217·81)	(4·98, 9·49)	(0·74, 0·96)
P-value vs. Placebo	<0·0001	<0·0001	<0·0001	<0·0001	
P-value vs. GBP510 10µg with AS03		<0·0001	0·0212		
P-value vs. GBP510 25µg with AS03				<0·0001	
SCR, n (%)	93 (100·00)	10 (100·00)	96 (100·00)	29 (64·44)	0 (0·00)
95% CI (lower, upper)	(96·11, 100·00)	(69·15, 100·00)	(96·23, 100·00)	(48·78, 78·13)	(0·00, 6·16)
P-value vs. placebo	<0·0001	<0·0001	<0·0001	<0·0001	
P-value vs. GBP510 10µg with AS03		NA	NA		
P-value vs. GBP510 25µg with AS03				<0·0001	
Visit 7 (4 weeks post-2 <sup>nd</sup> vaccination)					
n	93	10	96	45	58
GMC ± standard deviation (BAU/mL)	1,517·87 ± 2·09	132·64 ± 2·76	1,943·44 ± 1·79	114·97 ± 2·74	12·52 ± 1·71
95% CI (lower, upper)	(1,304·70, 1,765·87)	(64·23, 273·91)	(1,727·73, 2,186·08)	(84·90, 155·68)	(10·88, 14·42)
P-value vs. placebo	<0·0001	<0·0001	<0·0001	<0·0001	
P-value vs. GBP510 10µg with AS03		<0·0001	0·0113		
P-value vs. GBP510 25µg with AS03				<0·0001	
GMFR ± standard deviation	100·65 ± 2·55	12·12 ± 2·37	140·28 ± 2·06	7·03 ± 2·90	1·00 ± 1·93
95% CI (lower, upper)	(83·03, 122·01)	(6·54, 22·47)	(121·14, 162·44)	(5·11, 9·68)	(0·84, 1·19)
P-value vs. placebo	<0·0001	<0·0001	<0·0001	<0·0001	
P-value vs. GBP510 10µg with AS03		<0·0001	0·0071		
P-value vs. GBP510 25µg with AS03				<0·0001	
SCR, n (%)	92 (98·92)	10 (100·00)	96 (100·00)	28 (62·22)	1 (1·72)
95% CI (lower, upper)	(94·15, 99·97)	(69·15, 100·00)	(96·23, 100·00)	(46·54, 76·23)	(0·04, 9·24)
P-value vs. placebo	<0·0001	<0·0001	<0·0001	<0·0001	
P-value vs. GBP510 10µg with AS03		1·0000	0·4921		
P-value vs. GBP510 25µg with AS03				<0·0001	

GMC, geometric mean concentrations; GMFR, geometric mean fold rise; SCR, seroconversion rate; CI, confidence interval; BAU, binding antibody unit; NA, not applicable

GMFR = GMC (each visit) / GMC (Baseline)

SCR: Percentage of participants with  $\geq$  4-fold rise from baseline

%: n / (No. of subject who information was collected at each visit by group) \* 100

The 95% CI for GMC/GMFR is calculated based on the t-distribution of the log-transformed values for geometric means or geometric mean fold rises, then back transformed to the original scale for presentation.

The 95% CI for SCR is calculated by Clopper-Pearson Methods.

P-value versus placebo: p-value for difference of Treatment groups versus Placebo (continuous values are two sample t-test and categorical values are chi-square test or fisher's exact test)

P-value versus GBP510 10 $\mu$ g with AS03: p-value for difference of each group versus GBP510 10 $\mu$ g with AS03 (continuous values are two sample t-test and categorical values are chi-square test or fisher's exact test)

P-value versus GBP510 25 $\mu$ g with AS03: p-value for difference of each group versus GBP510 25 $\mu$ g with AS03 (continuous values are two sample t-test and categorical values are chi-square test or fisher's exact test)

n: number of participants

**Table S9. Geometric mean titers and seroconversion rates of neutralizing antibody to the SARS-CoV-2 by pseudovirus-based neutralization assay (per-protocol set)**

	10µg GBP510 with AS03 (N = 93)	10µg GBP510 (N = 10)	25µg GBP510 with AS03 (N = 96)	25µg GBP510 (N = 45)	Placebo (N = 58)
Geometric mean titer and seroconversion rate					
Baseline					
n	93	10	96	45	58
GMT ± standard deviation (IU/mL)	18·05 ± 1·28	21·01 ± 1·58	19·49 ± 1·43	19·05 ± 1·48	19·19 ± 1·51
95% CI (lower, upper)	(17·16, 18·99)	(15·16, 29·12)	(18·13, 20·95)	(16·94, 21·43)	(17·21, 21·39)
P-value vs. placebo	0·3126	0·5302	0·8043	0·9290	
P-value vs. GBP510 10µg with AS03		0·3266	0·0869		
P-value vs. GBP510 25µg with AS03				0·7321	
Visit 4 (4 weeks post-1 <sup>st</sup> vaccination)					
n	93	10	96	45	58
GMT± standard deviation (IU/mL)	39·97 ± 2·73	32·79 ± 2·45	40·94 ± 2·77	21·23 ± 1·65	19·71 ± 1·58
95% CI (lower, upper)	(32·51, 49·14)	(17·28, 62·23)	(33·31, 50·32)	(18·28, 24·65)	(17·48, 22·22)
P-value vs. placebo	<0·0001	0·1095	<0·0001	0·4327	
P-value vs. GBP510 10µg with AS03		0·5509	0·8705		
P-value vs. GBP510 25µg with AS03				<0·0001	
GMFR ± standard deviation	2·21 ± 2·78	1·56 ± 2·42	2·10 ± 2·92	1·11 ± 1·63	1·03 ± 1·91
95% CI (lower, upper)	(1·79, 2·73)	(0·83, 2·94)	(1·69, 2·61)	(0·96, 1·29)	(0·87, 1·22)
P-value vs. placebo	<0·0001	0·0776	<0·0001	0·4822	
P-value vs. GBP510 10µg with AS03		0·3011	0·7307		
P-value vs. GBP510 25µg with AS03				<0·0001	
SCR, n (%)	28 (30·11)	1 (10·00)	27 (28·13)	2 (4·44)	4 (6·90)
95% CI (lower, upper)	(21·03, 40·50)	(0·25, 44·50)	(19·42, 38·22)	(0·54, 15·15)	(1·91, 16·73)
P-value vs. placebo	0·0007	0·5604	0·0015	0·6938	
P-value vs. GBP510 10µg with AS03		0·2754	0·7642		
P-value vs. GBP510 25µg with AS03				0·0012	
Visit 6 (2 weeks post-2 <sup>nd</sup> vaccination)					
n	93	10	96	45	58
GMT ± standard deviation (IU/mL)	1,369·02 ± 2·60	83·47 ± 4·47	1,431·45 ± 2·69	63·85 ± 3·31	19·24 ± 1·47
95% CI (lower, upper)	(1,124·49, 1,666·73)	(28·62, 243·48)	(1,171·07, 1,749·73)	(44·55, 91·50)	(17·37, 21·31)

	<b>10µg GBP510 with AS03 (N = 93)</b>	<b>10µg GBP510 (N = 10)</b>	<b>25µg GBP510 with AS03 (N = 96)</b>	<b>25µg GBP510 (N = 45)</b>	<b>Placebo (N = 58)</b>
P-value vs. placebo	<0·0001	0·0127	<0·0001	<0·0001	
P-value vs. GBP510 10µg with AS03		0·0002	0·7533		
P-value vs. GBP510 25µg with AS03				<0·0001	
GMFR ± Standard deviation	75·83 ± 2·68	3·97 ± 4·09	73·44 ± 2·88	3·35 ± 3·44	1·00 ± 1·64
95% CI (lower, upper)	(61·91, 92·88)	(1·45, 10·88)	(59·30, 90·97)	(2·31, 4·86)	(0·88, 1·14)
P-value vs. placebo	<0·0001	0·0129	<0·0001	<0·0001	
P-value vs. GBP510 10µg with AS03		<0·0001	0·8300		
P-value vs. GBP510 25µg with AS03				<0·0001	
SCR, n (%)	93 (100·00)	5 (50·00)	95 (98·96)	23 (51·11)	1 (1·72)
95% CI (lower, upper)	(96·11, 100·00)	(18·71, 81·29)	(94·33, 99·97)	(35·77, 66·30)	(0·04, 9·24)
P-value vs. placebo	<0·0001	0·0001	<0·0001	<0·0001	
P-value vs. GBP510 10µg with AS03		<0·0001	1·0000		
P-value vs. GBP510 25µg with AS03				<0·0001	
Visit 7 (4 weeks post-2 <sup>nd</sup> vaccination)					
n	93	10	96	45	58
GMT ± standard deviation (IU/mL)	838·79 ± 2·74	68·52 ± 3·85	1,107·32 ± 2·61	51·87 ± 3·36	19·29 ± 1·49
95% CI (lower, upper)	(681·68, 1,032·11)	(26·12, 179·79)	(911·43, 1,345·31)	(36·05, 74·63)	(17·38, 21·41)
P-value vs. placebo	<0·0001	0·0157	<0·0001	<0·0001	
P-value vs. GBP510 10µg with AS03		<0·0001	0·0539		
P-value vs. GBP510 25µg with AS03				<0·0001	
GMFR ± Standard deviation	46·46 ± 2·78	3·26 ± 4·15	56·81 ± 2·95	2·72 ± 3·72	1·01 ± 1·72
95% CI (lower, upper)	(37·62, 57·37)	(1·18, 9·02)	(45·64, 70·72)	(1·84, 4·04)	(0·87, 1·16)
P-value vs. placebo	<0·0001	0·0284	<0·0001	<0·0001	
P-value vs. GBP510 10µg with AS03		<0·0001	0·1909		
P-value vs. GBP510 25µg with AS03				<0·0001	
SCR, n (%)	91 (97·85)	5 (50·00)	95 (98·96)	19 (42·22)	2 (3·45)
95% CI (lower, upper)	(92·45, 99·74)	(18·71, 81·29)	(94·33, 99·97)	(27·66, 57·85)	(0·42, 11·91)
P-value vs. placebo	<0·0001	0·0004	<0·0001	<0·0001	
P-value vs. GBP510 10µg with AS03		<0·0001	0·6171		
P-value vs. GBP510 25µg with AS03				<0·0001	

GMT, geometric mean titer; GMFR, geometric mean fold rise; SCR, seroconversion rate; CI, confidence interval

GMFR = GMT (each visit) / GMT (Baseline)

SCR: Percentage of participants with  $\geq$  4-fold rise from baseline

%: n / (No. of participant who information was collected at each visit by group) \* 100

The 95% CI for GMT/GMFR is calculated based on the t-distribution of the log-transformed values for geometric means or geometric mean fold rises, then back transformed to the original scale for presentation.

The 95% CI for SCR is calculated by Clopper-Pearson Methods.

P-value versus placebo: p-value for difference of Treatment groups versus Placebo (continuous values are two sample t-test and categorical values are chi-square test or fisher's exact test)

P-value versus GBP510 10 $\mu$ g with AS03: p-value for difference of each group versus GBP510 10 $\mu$ g with AS03 (continuous values are two sample t-test and categorical values are chi-square test or fisher's exact test)

P-value versus GBP510 25 $\mu$ g with AS03: p-value for difference of each group versus GBP510 25 $\mu$ g with AS03 (continuous values are two sample t-test and categorical values are chi-square test or fisher's exact test)

**Table S10. Geometric mean titers and seroconversion rates of neutralizing antibody to the SARS-CoV-2 by plaque reduction neutralization test (per-protocol set)**

	10µg GBP510 with AS03 (N = 93)	10µg GBP510 (N = 10)	25µg GBP510 with AS03 (N = 96)	25µg GBP510 (N = 45)	Placebo (N = 58)
Geometric mean titer and seroconversion rate					
Baseline					
N	23	4	21	9	19
GMT ± Standard deviation (IU/mL)	4·40±1·71	9·00±1·00	4·33±1·70	4·33±1·73	4·76±1·75
95% CI (lower, upper)	(3·49, 5·54)	(9·00, 9·00)	(3·40, 5·51)	(2·84, 6·60)	(3·64, 6·23)
P-value vs. Placebo	0·6367	<0·0001	0·5787	0·6713	
P-value vs. GBP510 10µg with AS03		<0·0001	0·9216		
P-value vs. GBP510 25µg with AS03				1·0000	
Visit 6 (2 weeks post-2 <sup>nd</sup> vaccination)					
N	23	4	21	9	19
GMT ± Standard deviation (IU/mL)	949·84±2·24	34·08±6·05	860·96±1·86	58·13±5·09	4·76±1·75
95% CI (lower, upper)	(670·40, 1,345·77)	(1·94, 597·40)	(649·60, 1,141·10)	(16·64, 203·13)	(3·64, 6·23)
P-value vs. Placebo	<0·0001	0·1156	<0·0001	0·0016	
P-value vs. GBP510 10µg with AS03		0·0320	0·6548		
P-value vs. GBP510 25µg with AS03				0·0009	
GMFR ± Standard deviation	216·06±2·04	3·79±6·05	198·99±1·83	13·44±4·50	1·00±1·00
95% CI (lower, upper)	(158·81, 293·95)	(0·22, 66·38)	(151·17, 261·93)	(4·23, 42·71)	(1·00, 1·00)
P-value vs. Placebo	<0·0001	0·2356	<0·0001	0·0008	
P-value vs. GBP510 10µg with AS03		0·0190	0·6827		
P-value vs. GBP510 25µg with AS03				0·0005	
SCR, n (%)	23 (100·00)	2 (50·00)	21 (100·00)	7 (77·78)	0 (0·00)
95% CI (lower, upper)	(85·18, 100·00)	(6·76, 93·24)	(83·89, 100·00)	(39·99, 97·19)	(0·00, 17·65)
P-value vs. Placebo	<0·0001	0·0237	<0·0001	<0·0001	
P-value vs. GBP510 10µg with AS03		0·0171	NA		
P-value vs. GBP510 25µg with AS03				0·0828	

GMT, geometric mean titer; GMFR, geometric mean fold rise; SCR, seroconversion rate; CI, confidence interval

GMFR = GMT (each visit) / GMT (Baseline)

SCR: Percentage of participants with ≥ 4-fold rise from baseline

%: n / (No. of subject who information was collected at each visit by group) \* 100

The 95% CI for GMT/GMFR is calculated based on the t-distribution of the log-transformed values for geometric means or geometric mean fold rises, then back transformed to the original scale for presentation.  
The 95% CI for SCR is calculated by Clopper-Pearson Methods.

P-value vs Placebo: P-value for difference of Treatment groups versus Placebo (continuous values are two sample t-test and categorical values are chi-square test or fisher's exact test.)

P-value vs GBP510 10 $\mu$ g with AS03: P-value for difference of each group versus GBP510 10 $\mu$ g with AS03 (continuous values are two sample t-test and categorical values are chi-square test or fisher's exact test.)

P-value vs GBP510 25 $\mu$ g with AS03: P-value for difference of each group versus GBP510 25 $\mu$ g with AS03 (continuous values are two sample t-test and categorical values are chi-square test or fisher's exact test.)

n: number of participants

**Table S11. Geometric mean concentration and seroconversion rate of IgG antibody to the SARS-CoV-2-RBD in adults aged 19-64 years: analysis by enzyme-linked immunosorbent assay (per-protocol set)**

	10µg GBP510 with AS03 (N=81)	10µg GBP510 (N=10)	25µg GBP510 with AS03 (N=85)	25µg GBP510 (N=41)	Placebo (N=53)
Geometric mean titer and seroconversion rate					
Baseline					
n	81	10	85	41	53
GMC±standard deviation (BAU/mL)	14·72±1·72	10·95±1·61	13·18±1·67	16·24±1·70	12·20±1·63
95% CI (lower, upper)	(13·06, 16·59)	(7·78, 15·40)	(11·81, 14·72)	(13·4, 19·20)	(10·66, 13·97)
P-value vs. Placebo	0·0441	0·5220	0·3820	0·0081	
P-value vs. 10µg GBP510 with AS03		0·1020	0·1799		
P-value vs. 25µg GBP510 with AS03				0·0360	
Visit 4 (4 weeks post-1 <sup>st</sup> vaccination)					
n	81	10	85	41	53
GMC±standard deviation (BAU/mL)	121·33±1·94	37·72±2·03	135·87±2·03	29·65±1·72	12·66±1·71
95% CI (lower, upper)	(104·75, 140·53)	(22·74, 62·56)	(116·57, 158·37)	(24·97, 35·20)	(10·92, 14·67)
P-value vs. Placebo	<0·0001	<0·0001	<0·0001	<0·0001	
P-value vs. 10µg GBP510 with AS03		<0·0001	0·2912		
P-value vs. 25µg GBP510 with AS03				<0·0001	
GMFR±standard deviation	8·24±2·33	3·45±1·91	10·31±2·23	1·83±1·94	1·04±1·88
95% CI (lower, upper)	(6·84, 9·94)	(2·17, 5·47)	(8·67, 12·26)	(1·48, 2·25)	(0·87, 1·23)
P-value vs. Placebo	<0·0001	<0·0001	<0·0001	<0·0001	
P-value vs. 10µg GBP510 with AS03		0·0023	0·0835		
P-value vs. 25µg GBP510 with AS03				<0·0001	
SCR, n (%)	63 (77·78)	4 (40·00)	75 (88·24)	5 (12·20)	0 (0·00)
95% CI (lower, upper)	(67·17, 86·27)	(12·16, 73·76)	(79·43, 94·21)	(4·08, 26·20)	(0·00, 6·72)
P-value vs. Placebo	<0·0001	0·0004	<0·0001	0·0137	
P-value vs. 10µg GBP510 with AS03		0·0189	0·0721		
P-value vs. 25µg GBP510 with AS03				<0·0001	

	<b>10µg GBP510 with AS03 (N=81)</b>	<b>10µg GBP510 (N=10)</b>	<b>25µg GBP510 with AS03 (N=85)</b>	<b>25µg GBP510 (N=41)</b>	<b>Placebo (N=53)</b>
Visit 6 (2 weeks post-2nd vaccination)					
n	81	10	85	41	53
GMC±standard deviation (BAU/mL)	2,368·72±1·72	155·30±3·05	2,777·08±1·71	114·64±2·69	10·37±1·62
95% CI (lower, upper)	(2,100·72, 2,670·91)	(70·02, 344·47)	(2,475·11, 3,115·90)	(83·84, 156·75)	(9·07, 11·85)
P-value vs. Placebo	<0·0001	<0·0001	<0·0001	<0·0001	
P-value vs. 10µg GBP510 with AS03		<0·0001	0·0588		
P-value vs. 25µg GBP510 with AS03				<0·0001	
GMFR±standard deviation	160·95±2·15	14·19±2·58	210·65±1·85	7·06±2·86	0·85±1·67
95% CI (lower, upper)	(135·85, 190·70)	(7·21, 27·92)	(184·50, 240·50)	(5·07, 9·83)	(0·74, 0·98)
P-value vs. Placebo	<0·0001	<0·0001	<0·0001	<0·0001	
P-value vs. 10µg GBP510 with AS03		<0·0001	0·0140		
P-value vs. 25µg GBP510 with AS03				<0·0001	
SCR, n (%)	81 (100·00)	10 (100·00)	85 (100·00)	27 (65·85)	0 (0·00)
95% CI (lower, upper)	(95·55, 100·00)	(69·15, 100·00)	(95·75, 100·00)	(49·41, 79·92)	(0·00, 6·72)
P-value vs. Placebo	<0·0001	<0·0001	<0·0001	<0·0001	
P-value vs. 10µg GBP510 with AS03		NA	NA		
P-value vs. 25µg GBP510 with AS03				<0·0001	
Visit 7 (4 weeks post-2nd vaccination)					
n	81	10	85	41	53
GMC±standard deviation (BAU/mL)	1,628·59±2·02	132·64±2·76	2,073·65±1·61	119·45±2·71	12·51±1·71
95% CI (lower, upper)	(1,393·34, 1,903·56)	(64·23, 273·91)	(1,870·12, 2,299·33)	(87·24, 163·56)	(10·78, 14·51)
P-value vs. Placebo	<0·0001	<0·0001	<0·0001	<0·0001	
P-value vs. 10µg GBP510 with AS03		<0·0001	0·0112		
P-value vs. 25µg GBP510 with AS03				<0·0001	
GMFR±standard deviation	110·66±2·48	12·12±2·37	157·29±1·83	7·35±2·85	1·03±1·96
95% CI (lower, upper)	(90·50, 135·32)	(6·54, 22·47)	(138·08, 179·18)	(5·29, 10·23)	(0·85, 1·23)
P-value vs. Placebo	<0·0001	<0·0001	<0·0001	<0·0001	
P-value vs. 10µg GBP510 with AS03		<0·0001	0·0041		
P-value vs. 25µg GBP510 with AS03				<0·0001	

	<b>10µg GBP510 with AS03 (N=81)</b>	<b>10µg GBP510 (N=10)</b>	<b>25µg GBP510 with AS03 (N=85)</b>	<b>25µg GBP510 (N=41)</b>	<b>Placebo (N=53)</b>
SCR, n (%)	80 (98·77)	10 (100·00)	85 (100·00)	26 (63·41)	1 (1·89)
95% CI (lower, upper)	(93·31, 99·97)	(69·15, 100·00)	(95·75, 100·00)	(46·94, 77·88)	(0·05, 10·07)
P-value vs. Placebo	<0·0001	<0·0001	<0·0001	<0·0001	
P-value vs. 10µg GBP510 with AS03		1·0000	0·4880		
P-value vs. 25µg GBP510 with AS03				<0·0001	

GMC (Geometric Mean Concentration); GMFR, geometric mean fold rise; SCR, seroconversion rate; CI, confidence interval; BAU, binding antibody unit; NA, not applicable

GMFR (Geometric Mean Fold Rise) = GMC (each visit) / GMC (Baseline)

SCR (Seroconversion rate): Percentage of participants with  $\geq 4$ -fold rise from baseline

CI (Confidence Interval)

%: n / (No. of subject who information was collected at each visit by group) \* 100

The 95% CI for GMC/GMFR is calculated based on the t-distribution of the log-transformed values for geometric means or geometric mean fold rises, then back transformed to the original scale for presentation.

The 95% CI for SCR is calculated by Clopper-Pearson Methods.

P-value vs Placebo: P-value for difference of Treatment groups versus Placebo (continuous values are two sample t-test and categorical values are chi-square test or fisher's exact test.)

P-value vs GBP510 10ug with AS03: P-value for difference of each group versus GBP510 10ug with AS03 (continuous values are two sample t-test and categorical values are chi-square test or fisher's exact test.)

P-value vs GBP510 25ug with AS03: P-value for difference of each group versus GBP510 25ug with AS03 (continuous values are two sample t-test and categorical values are chi-square test or fisher's exact test.)

n = number of participants

**Table S12. Geometric mean titers and seroconversion rates of neutralizing antibody to the SARS-CoV-2 in adult aged 19-64 years: analysis by pseudovirus-based neutralization assay (per-protocol set)**

	10µg GBP510 with AS03 (N = 81)	10µg GBP510 (N = 10)	25µg GBP510 with AS03 (N = 85)	25µg GBP510 (N = 41)	Placebo (N = 53)
Geometric mean titer and seroconversion rate					
Baseline					
n	81	10	85	41	53
GMT ± standard deviation (IU/mL)	18·22±1·30	21·01±1·58	19·68±1·45	18·47±1·38	19·41±1·54
95% CI (lower, upper)	(17·19, 19·30)	(15·16, 29·12)	(18·16, 21·32)	(16·70, 20·43)	(17·24, 21·86)
P-value vs. placebo	0·3394	0·5992	0·8426	0·5397	
P-value vs. GBP510 10µg with AS03		0·3562	0·1229		
P-value vs. GBP510 25µg with AS03				0·3516	
Visit 4 (4 weeks post-1 <sup>st</sup> vaccination)					
N	81	10	85	41	53
GMT± standard deviation (IU/mL)	38·87±2·69	32·79±2·45	43·19±2·79	21·03±1·64	19·98±1·61
95% CI (lower, upper)	(31·22, 48·38)	(17·28, 62·23)	(34·62, 53·87)	(18·01, 24·57)	(17·53, 22·78)
P-value vs. placebo	<0·0001	0·1191	<0·0001	0·6107	
P-value vs. GBP510 10µg with AS03		0·6067	0·5017		
P-value vs. GBP510 25µg with AS03				<0·0001	
GMFR ± standard deviation	2·13±2·75	1·56±2·42	2·19±2·95	1·14±1·65	1·03±1·96
95% CI (lower, upper)	(1·71, 2·67)	(0·83, 2·94)	(1·74, 2·77)	(0·97, 1·33)	(0·85, 1·24)
P-value vs. placebo	<0·0001	0·0939	<0·0001	0·4262	
P-value vs. GBP510 10µg with AS03		0·3527	0·8626		
P-value vs. GBP510 25µg with AS03				<0·0001	
SCR, n (%)	23 (28·40)	1 (10·00)	25 (29·41)	2 (4·88)	4 (7·55)
95% CI (lower, upper)	(18·93, 39·50)	(0·25, 44·50)	(20·02, 40·29)	(0·60, 16·53)	(2·09, 18·21)
P-value vs. placebo	0·0033	1·0000	0·0022	0·6933	
P-value vs. GBP510 10µg with AS03		0·2810	0·8852		
P-value vs. GBP510 25µg with AS03				0·0017	
Visit 6 (2 weeks post-2 <sup>nd</sup> vaccination)					
N	81	10	85	41	53
GMT ± standard deviation (IU/mL)	1,536·69±2·43	83·47±4·47	1,622·50±2·42	62·04±3·22	19·46±1·50
95% CI (lower, upper)	(1,262·76, 1,870·03)	(28·62, 243·48)	(1,340·93, 1,963·20)	(42·88, 89·77)	(17·41, 21·76)

	<b>10µg GBP510 with AS03 (N = 81)</b>	<b>10µg GBP510 (N = 10)</b>	<b>25µg GBP510 with AS03 (N = 85)</b>	<b>25µg GBP510 (N = 41)</b>	<b>Placebo (N = 53)</b>
P-value vs. placebo	<0·0001	0·0132	<0·0001	<0·0001	
P-value vs. GBP510 10µg with AS03		0·0001	0·6933		
P-value vs. GBP510 25µg with AS03				<0·0001	
GMFR ± Standard deviation	84·36±2·54	3·97±4·09	82·46±2·61	3·36±3·35	1·00±1·68
95% CI (lower, upper)	(68·64, 103·68)	(1·45, 10·88)	(67·05, 101·41)	(2·29, 4·92)	(0·87, 1·16)
P-value vs. placebo	<0·0001	0·0129	<0·0001	<0·0001	
P-value vs. GBP510 10µg with AS03		<0·0001	0·8767		
P-value vs. GBP510 25µg with AS03				<0·0001	
SCR, n (%)	81 (100·00)	5 (50·00)	85 (100·00)	22 (53·66)	1 (1·89)
95% CI (lower, upper)	(95·55, 100·00)	(18·71, 81·29)	(95·75, 100·00)	(37·42, 69·34)	(0·05, 10·07)
P-value vs. placebo	<0·0001	0·0002	<0·0001	<0·0001	
P-value vs. GBP510 10µg with AS03		<0·0001	NA		
P-value vs. GBP510 25µg with AS03				<0·0001	
Visit 7 (4 weeks post-2 <sup>nd</sup> vaccination)					
N	81	10	85	41	53
GMT ± standard deviation (IU/mL)	916·92±2·64	68·52±3·85	1,222·02±2·42	52·99±3·36	19·52±1·51
95% CI (lower, upper)	(740·07, 1,136·03)	(26·12, 179·79)	(1,009·72, 1,478·94)	(36·14, 77·69)	(17·42, 21·88)
P-value vs. placebo	<0·0001	0·0165	<0·0001	<0·0001	
P-value vs. GBP510 10µg with AS03		<0·0001	0·0476		
P-value vs. GBP510 25µg with AS03				<0·0001	
GMFR ± Standard deviation	50·34±2·71	3·26±4·15	62·10±2·77	2·87±3·54	1·01±1·77
95% CI (lower, upper)	(40·39, 62·73)	(1·18, 9·02)	(49·86, 77·36)	(1·93, 4·27)	(0·86, 1·18)
P-value vs. placebo	<0·0001	0·0285	<0·0001	<0·0001	
P-value vs. GBP510 10µg with AS03		<0·0001	0·1811		
P-value vs. GBP510 25µg with AS03				<0·0001	
SCR, n (%)	79 (97·53)	5 (50·00)	85 (100·00)	18 (43·90)	2 (3·77)
95% CI (lower, upper)	(91·36, 99·70)	(18·71, 81·29)	(95·75, 100·00)	(28·47, 60·25)	(0·46, 12·98)
P-value vs. placebo	<0·0001	0·0006	<0·0001	<0·0001	
P-value vs. GBP510 10µg with AS03		0·0001	0·2366		
P-value vs. GBP510 25µg with AS03				<0·0001	

GMT, geometric mean titer; GMFR, geometric mean fold rise; SCR, seroconversion rate; CI, confidence interval

GMFR = GMT (each visit) / GMT (Baseline)

SCR: Percentage of participants with  $\geq$  4-fold rise from baseline

%: n / (No. of participant who information was collected at each visit by group) \* 100

The 95% CI for GMT/GMFR is calculated based on the t-distribution of the log-transformed values for geometric means or geometric mean fold rises, then back transformed to the original scale for presentation.

The 95% CI for SCR is calculated by Clopper-Pearson Methods.

P-value versus placebo: p-value for difference of Treatment groups versus Placebo (continuous values are two sample t-test and categorical values are chi-square test or fisher's exact test)

P-value versus GBP510 10 $\mu$ g with AS03: p-value for difference of each group versus GBP510 10 $\mu$ g with AS03 (continuous values are two sample t-test and categorical values are chi-square test or fisher's exact test)

P-value versus GBP510 25 $\mu$ g with AS03: p-value for difference of each group versus GBP510 25 $\mu$ g with AS03 (continuous values are two sample t-test and categorical values are chi-square test or fisher's exact test)

**Table S13. Geometric mean concentration and seroconversion rate of IgG antibody to the SARS-CoV-2-RBD in adults aged ≥65 years: analysis by enzyme-linked immunosorbent assay (per-protocol set)**

	10µg GBP510 with AS03 (N=12)	10µg GBP510 (N=0)	25µg GBP510 with AS03 (N=11)	25µg GBP510 (N=4)	Placebo (N=5)
Geometric mean titer and seroconversion rate					
Baseline					
n	12	0	11	4	5
GMC±standard deviation (BAU/mL)	17·78±1·45		20·33±1·86	17·42±1·11	16·24±1·71
95% CI (lower, upper)	(14·02, 22·55)		(13·39, 30·86)	(14·69, 20·67)	(8·34, 31·61)
P-value vs. Placebo	0·6933		0·4977	0·7875	
P-value vs. 10µg GBP510 with AS03			0·5337		
P-value vs. 25µg GBP510 with AS03				0·4449	
Visit 4 (4 weeks post-1 <sup>st</sup> vaccination)					
N	12	0	11	4	5
GMC±standard deviation (BAU/mL)	64·57±2·74		86·36±2·38	20·05±1·56	13·24±1·80
95% CI (lower, upper)	(34·03, 122·49)		(48·22, 154·67)	(9·89, 40·65)	(6·39, 27·44)
P-value vs. Placebo	0·0053		0·0007	0·2815	
P-value vs. 10µg GBP510 with AS03			0·4684		
P-value vs. 25µg GBP510 with AS03				0·0075	
GMFR±standard deviation	3·63±2·79		4·25±2·30	1·15±1·64	0·82±2·30
95% CI (lower, upper)	(1·89, 6·98)		(2·43, 7·44)	(0·52, 2·53)	(0·29, 2·30)
P-value vs. Placebo	0·0118		0·0025	0·4918	
P-value vs. 10µg GBP510 with AS03			0·6933		
P-value vs. 25µg GBP510 with AS03				0·0122	
SCR, n (%)	5 (41·67)	0 (-)	4 (36·36)	0 (0·00)	0 (0·00)
95% CI (lower, upper)	(15·17, 72·33)		(10·93, 69·21)	(0·00, 60·24)	(0·00, 52·18)
P-value vs. Placebo	0·2445		0·2445	NA	
P-value vs. 10µg GBP510 with AS03			1·0000		
P-value vs 25µg GBP510 with AS03				0·5165 f	

	<b>10µg GBP510 with AS03 (N=12)</b>	<b>10µg GBP510 (N=0)</b>	<b>25µg GBP510 with AS03 (N=11)</b>	<b>25µg GBP510 (N=4)</b>	<b>Placebo (N=5)</b>
Visit 6 (2 weeks post-2nd vaccination)					
n	12	0	11	4	5
GMC±standard deviation (BAU/mL)	1,173·91±2·40		1,558·54±2·62	91·89±3·93	12·82±1·79
95% CI (lower, upper)	(673·04, 2,047·53)		(815·94, 2,976·98)	(10·39, 812·45)	(6·21, 26·45)
P-value vs. Placebo	<0·0001		<0·0001	0·0218	
P-value vs. 10µg GBP510 with AS03			0·4679		
P-value vs. 25µg GBP510 with AS03				0·0006	
GMFR±standard deviation	66·03±2·69		76·67±2·70	5·27±4·24	0·79±1·63
95% CI (lower, upper)	(35·20, 123·86)		(39·34, 149·41)	(0·53, 52·50)	(0·43, 1·45)
P-value vs. Placebo	<0·0001		<0·0001	0·0269	
P-value vs. 10µg GBP510 with AS03			0·7217		
P-value vs. 25µg GBP510 with AS03				0·0012	
SCR, n (%)	12 (100·00)	0 (-)	11 (100·00)	2 (50·00)	0 (0·00)
95% CI (lower, upper)	(73·54, 100·00)		(71·51, 100·00)	(6·76, 93·24)	(0·00, 52·18)
P-value vs. Placebo	0·0002		0·0002	0·1667	
P-value vs. 10µg GBP510 with AS03			NA		
P-value vs. 25µg GBP510 with AS03				0·0571	
Visit 7 (4 weeks post-2nd vaccination)					
n	12	0	11	4	5
GMC±standard deviation (BAU/mL)	943·74±2·19		1,177·45±2·67	77·68±3·39	12·70±1·74
95% CI (lower, upper)	(573·91, 1,551·88)		(608·78, 2,277·31)	(11·13, 542·43)	(6·40, 25·19)
P-value vs. Placebo	<0·0001		<0·0001	0·0201	
P-value vs. 10µg GBP510 with AS03			0·5548		
P-value vs. 25µg GBP510 with AS03				0·0006	
GMFR±standard deviation	53·08±2·41		57·92±2·64	4·46±3·70	0·78±1·50
95% CI (lower, upper)	(30·38, 92·74)		(30·18, 111·16)	(0·56, 35·68)	(0·47, 1·29)
P-value vs. Placebo	<0·0001		<0·0001	0·0717	
P-value vs. 10µg GBP510 with AS03			0·8230		
P-value vs 25µg GBP510 with AS03				0·0011	

	<b>10µg GBP510 with AS03 (N=12)</b>	<b>10µg GBP510 (N=0)</b>	<b>25µg GBP510 with AS03 (N=11)</b>	<b>25µg GBP510 (N=4)</b>	<b>Placebo (N=5)</b>
SCR, n (%)	12 (100·00)	0 (-)	11 (100·00)	2 (50·00)	0 (0·00)
95% CI (lower, upper)	(73·54, 100·00)		(71·51, 100·00)	(6·76, 93·24)	(0·00, 52·18)
P-value vs. Placebo	0·0002		0·0002	0·1667	
P-value vs. 10µg GBP510 with AS03			NA		
P-value vs. 25µg GBP510 with AS03				0·0571	

GMC (Geometric Mean Concentration); GMFR, geometric mean fold rise; SCR, seroconversion rate; CI, confidence interval; BAU, binding antibody unit; NA, not applicable

GMFR (Geometric Mean Fold Rise) = GMC (each visit) / GMC (Baseline)

SCR (Seroconversion rate): Percentage of participants with  $\geq 4$ -fold rise from baseline

CI (Confidence Interval)

%: n / (No. of subject who information was collected at each visit by group) \* 100

The 95% CI for GMC/GMFR is calculated based on the t-distribution of the log-transformed values for geometric means or geometric mean fold rises, then back transformed to the original scale for presentation.

The 95% CI for SCR is calculated by Clopper-Pearson Methods.

P-value vs Placebo: P-value for difference of Treatment groups versus Placebo (continuous values are two sample t-test and categorical values are chi-square test or fisher's exact test.)

P-value vs GBP510 10ug with AS03: P-value for difference of each group versus GBP510 10ug with AS03 (continuous values are two sample t-test and categorical values are chi-square test or fisher's exact test.)

P-value vs GBP510 25ug with AS03: P-value for difference of each group versus GBP510 25ug with AS03 (continuous values are two sample t-test and categorical values are chi-square test or fisher's exact test.)

n = number of participants

**Table S14. Geometric mean titers and seroconversion rates of neutralizing antibody to the SARS-CoV-2 in adult aged ≥65 years: analysis by pseudovirus-based neutralization assay (per-protocol set)**

	10µg GBP510 with AS03 (N = 12)	10µg GBP510 (N = 0)	25µg GBP510 with AS03 (N = 11)	25µg GBP510 (N = 4)	Placebo (N = 5)
Geometric mean titer and seroconversion rate					
Baseline					
n	12	0	11	4	5
GMT ± standard deviation (IU/mL)	17·00±1·00		18·11±1·23	26·14±2·36	17·00±1·00
95% CI (lower, upper)	(17·00, 17·00)		(15·73, 20·83)	(6·65, 102·76)	(17·00, 17·00)
P-value vs. placebo	NA		0·3409	0·3910 t	
P-value vs. GBP510 10µg with AS03			0·3409		
P-value vs. GBP510 25µg with AS03				0·4581	
Visit 4 (4 weeks post-1 <sup>st</sup> vaccination)					
n	12	0	11	4	5
GMT± standard deviation (IU/mL)	48·31±3·04		27·12±2·47	23·30±1·88	17·00±1·00
95% CI (lower, upper)	(23·82, 97·97)		(14·76, 49·81)	(8·54, 63·55)	(17·00, 17·00)
P-value vs. placebo	0·0077		0·1178	0·3910	
P-value vs. GBP510 10µg with AS03			0·1891		
P-value vs. GBP510 25µg with AS03				0·7646	
GMFR ± standard deviation	2·84±3·04		1·50±2·62	0·89±1·26	1·00±1·00
95% CI (lower, upper)	(1·40, 5·76)		(0·78, 2·86)	(0·62, 1·28)	(1·00, 1·00)
P-value vs. placebo	0·0077		0·1944	0·3910 t	
P-value vs. GBP510 10µg with AS03			0·1566		
P-value vs. GBP510 25µg with AS03				0·1218 t	
SCR, n (%)	5 (41·67)	0 (-)	2 (18·18)	0 (0·00)	0 (0·00)
95% CI (lower, upper)	(15·17, 72·33)		(2·28, 51·78)	(0·00, 60·24)	(0·00, 52·18)
P-value vs. placebo	0·2445		1·0000	NA	
P-value vs. GBP510 10µg with AS03			0·3707		
P-value vs. GBP510 25µg with AS03				1·0000	
Visit 6 (2 weeks post-2 <sup>nd</sup> vaccination)					
n	12	0	11	4	5
GMT ± standard deviation (IU/mL)	627·68±2·91		543·68±3·55	85·71±5·08	17·00±1·00
95% CI (lower, upper)	(318·55, 1,236·78)		(232·19, 1,273·06)	(6·45, 1,138·93)	(17·00, 17·00)

	<b>10µg GBP510 with AS03 (N = 12)</b>	<b>10µg GBP510 (N = 0)</b>	<b>25µg GBP510 with AS03 (N = 11)</b>	<b>25µg GBP510 (N = 4)</b>	<b>Placebo (N = 5)</b>
P-value vs. placebo	<0·0001		<0·0001	0·1406	
P-value vs. GBP510 10µg with AS03			0·7709		
P-value vs. GBP510 25µg with AS03				0·0365	
GMFR ± Standard deviation	36·92±2·91		30·03±3·93	3·28±5·56	1·00±1·00
95% CI (lower, upper)	(18·74, 72·75)		(11·97, 75·33)	(0·21, 50·23)	(1·00, 1·00)
P-value vs. placebo	<0·0001		<0·0001 t	0·2601	
P-value vs. GBP510 10µg with AS03			0·6891 t		
P-value vs. GBP510 25µg with AS03				0·0218	
SCR, n (%)	12 (100·00)	0 (-)	10 (90·91)	1 (25·00)	0 (0·00)
95% CI (lower, upper)	(73·54, 100·00)		(58·72, 99·77)	(0·63, 80·59)	(0·00, 52·18)
P-value vs. placebo	0·0002		0·0014	0·4444	
P-value vs. GBP510 10µg with AS03			0·4783		
P-value vs. GBP510 25µg with AS03				0·0330	
Visit 7 (4 weeks post-2 <sup>nd</sup> vaccination)					
n	12	0	11	4	5
GMT ± standard deviation (IU/mL)	459·81±2·99		517·02±3·37	41·70±3·88	17·00±1·00
95% CI (lower, upper)	(229·26, 922·22)		(228·65, 1,169·08)	(4·82, 361·16)	(17·00, 17·00)
P-value vs. placebo	<0·0001		<0·0001	0·2777	
P-value vs. GBP510 10µg with AS03			0·8100		
P-value vs. GBP510 25µg with AS03				0·0043	
GMFR ± Standard deviation	27·05±2·99		28·56±3·83	1·60±6·69	1·00±1·00
95% CI (lower, upper)	(13·49, 54·25)		(11·58, 70·40)	(0·08, 32·80)	(1·00, 1·00)
P-value vs. placebo	<0·0001		<0·0001	0·6566	
P-value vs. GBP510 10µg with AS03			0·9161		
P-value vs. GBP510 25µg with AS03				0·0056	
SCR, n (%)	12 (100·00)	0 (-)	10 (90·91)	1 (25·00)	0 (0·00)
95% CI (lower, upper)	(73·54, 100·00)		(58·72, 99·77)	(0·63, 80·59)	(0·00, 52·18)
P-value vs. placebo	0·0002		0·0014	0·4444	
P-value vs. GBP510 10µg with AS03			0·4783		
P-value vs. GBP510 25µg with AS03				0·0330	

GMT, geometric mean titer; GMFR, geometric mean fold rise; SCR, seroconversion rate; CI, confidence interval

GMFR = GMT (each visit) / GMT (Baseline)

SCR: Percentage of participants with  $\geq$  4-fold rise from baseline

%: n / (No. of participant who information was collected at each visit by group) \* 100

The 95% CI for GMT/GMFR is calculated based on the t-distribution of the log-transformed values for geometric means or geometric mean fold rises, then back transformed to the original scale for presentation.

The 95% CI for SCR is calculated by Clopper-Pearson Methods.

P-value versus placebo: p-value for difference of Treatment groups versus Placebo (continuous values are two sample t-test and categorical values are chi-square test or fisher's exact test)

P-value versus GBP510 10 $\mu$ g with AS03: p-value for difference of each group versus GBP510 10 $\mu$ g with AS03 (continuous values are two sample t-test and categorical values are chi-square test or fisher's exact test)

P-value versus GBP510 25 $\mu$ g with AS03: p-value for difference of each group versus GBP510 25 $\mu$ g with AS03 (continuous values are two sample t-test and categorical values are chi-square test or fisher's exact test)

**Table S15. Cell-mediated response for CD4+ T cells expressing cytokines using intracellular cytokine staining (per-protocol set)**

	10µg GBP510 with AS03 (N=93)	10µg GBP510 (N=10)	25µg GBP510 with AS03 (N=96)	25µg GBP510 (N=45)	Placebo (N=58)
IFN-γ					
Baseline (day 0)					
n	19	2	17	7	15
Median	0.00	0.01	0.01	0.01	0.00
IQR (Q1, Q3)	(0.00, 0.04)	(0.00, 0.01)	(0.00, 0.02)	(0.00, 0.03)	(0.00, 0.01)
Visit 4 (day 28)					
n	19	2	17	7	15
Median	0.01	0.01	0.03	0.01	0.01
IQR (Q1, Q3)	(0.00, 0.04)	(0.00, 0.01)	(0.01, 0.06)	(0.00, 0.07)	(0.00, 0.03)
Visit 6 (day 42)					
n	19	2	17	7	15
Median	0.06	0.00	0.06	0.02	0.02
IQR (Q1, Q3)	(0.02, 0.11)	(0.00, 0.01)	(0.01, 0.12)	(0.01, 0.04)	(0.00, 0.04)
TNFα					
Baseline (day 0)					
n	19	2	17	7	15
Median	0.06	0.06	0.05	0.03	0.02
IQR (Q1, Q3)	(0.02, 0.20)	(0.04, 0.09)	(0.03, 0.08)	(0.00, 0.07)	(0.01, 0.06)
Visit 4 (day 28)					
n	19	2	17	7	15
Median	0.13	0.03	0.09	0.13	0.09
IQR (Q1, Q3)	(0.06, 0.30)	(0.00, 0.06)	(0.03, 0.35)	(0.06, 0.32)	(0.04, 0.26)
Visit 6 (day 42)					
n	19	2	17	7	15
Median	0.24	0.18	0.27	0.25	0.12
IQR (Q1, Q3)	(0.19, 0.59)	(0.02, 0.34)	(0.10, 0.52)	(0.04, 0.32)	(0.05, 0.49)
IL-2					
Baseline (day 0)					
n	19	2	17	7	15


	<b>10µg GBP510 with AS03 (N=93)</b>	<b>10µg GBP510 (N=10)</b>	<b>25µg GBP510 with AS03 (N=96)</b>	<b>25µg GBP510 (N=45)</b>	<b>Placebo (N=58)</b>
Median	0.01	0.01	0.01	0.01	0.01
IQR (Q1, Q3)	(0.01, 0.03)	(0.01, 0.01)	(0.00, 0.02)	(0.00, 0.02)	(0.00, 0.02)
Visit 4 (day 28)					
n	19	2	17	7	15
Median	0.03	0.02	0.03	0.02	0.02
IQR (Q1, Q3)	(0.01, 0.04)	(0.00, 0.03)	(0.01, 0.05)	(0.00, 0.04)	(0.00, 0.04)
Visit 6 (day 42)					
n	19	2	17	7	15
Median	0.11	0.02	0.10	0.04	0.01
IQR (Q1, Q3)	(0.07, 0.13)	(0.01, 0.03)	(0.04, 0.15)	(0.01, 0.04)	(0.00, 0.06)
IL-4					
Baseline (day 0)					
n	19	2	17	7	15
Median	0.01	0.04	0.01	0.00	0.02
IQR (Q1, Q3)	(0.00, 0.03)	(0.00, 0.08)	(0.00, 0.10)	(0.00, 0.04)	(0.00, 0.04)
Visit 4 (day 28)					
n	19	2	17	7	15
Median	0.00	0.00	0.02	0.02	0.01
IQR (Q1, Q3)	(0.00, 0.02)	(0.00, 0.00)	(0.01, 0.04)	(0.00, 0.10)	(0.00, 0.12)
Visit 6 (day 42)					
n	19	2	17	7	15
Median	0.00	0.00	0.00	0.00	0.01
IQR (Q1, Q3)	(0.00, 0.06)	(0.00, 0.00)	(0.00, 0.05)	(0.00, 0.04)	(0.00, 0.04)
IL-5					
Baseline (day 0)					
n	19	2	17	7	15
Median	0.00	0.00	0.00	0.00	0.00
IQR (Q1, Q3)	(0.00, 0.01)	(0.00, 0.00)	(0.00, 0.00)	(0.00, 0.00)	(0.00, 0.00)
Visit 4 (day 28)					
n	19	2	17	7	15
Median	0.00	0.00	0.00	0.00	0.00
IQR (Q1, Q3)	(0.00, 0.00)	(0.00, 0.00)	(0.00, 0.01)	(0.00, 0.01)	(0.00, 0.01)

	<b>10µg GBP510 with AS03 (N=93)</b>	<b>10µg GBP510 (N=10)</b>	<b>25µg GBP510 with AS03 (N=96)</b>	<b>25µg GBP510 (N=45)</b>	<b>Placebo (N=58)</b>
Visit 6 (day 42)					
n	19	2	17	7	15
Median	0.00	0.00	0.00	0.00	0.00
IQR (Q1, Q3)	(0.00, 0.00)	(0.00, 0.00)	(0.00, 0.01)	(0.00, 0.01)	(0.00, 0.01)


N= Total number of participants in each vaccine group; n = number of participants in each visit; IQR=Interquartile range; Q1=Quartile 3; Q3=Quartile 3.

RBD-specific CD4+ T cells producing the indicated cytokine as a fraction of total cytokine-producing RBD-specific CD4+ T cells.


**Figure S1. Clinical trial scheme.**




**Figure S2. Boxplot for the IFN- $\gamma$  (A), TNF- $\alpha$  (B), IL-2 (C), IL-4 (D), IL-5 (E) of cell-mediated immune responses for CD4+ T-cells expressing cytokines using intracellular cytokine staining at baseline (day 0), visit 4 (day 28) and visit 6 (day 42).**




(B)




(C)




(D)




(E)




**Figure S3. Age-stratified analysis of solicited local (A) and systemic (B) adverse events within 7 days after first-dose and second-dose (proportion of participants with adverse events).**





(B)

**Figure S4. Cross-reactive immunogenicity against the delta variant virus (B·1·617) in 25 µg GBP510 adjuvanted with AS03 recipients, assessed by the plaque reduction neutralization test (PRNT). Data from randomly selected 11 participants aged 19–85 years (A). Data from randomly selected 11 participants aged  $\geq$  65 years.**



(B)

